Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 9
1966 24
1967 18
1968 32
1969 33
1970 45
1971 41
1972 52
1973 46
1974 40
1975 42
1976 66
1977 85
1978 134
1979 143
1980 99
1981 134
1982 138
1983 154
1984 187
1985 203
1986 212
1987 181
1988 171
1989 192
1990 153
1991 168
1992 127
1993 113
1994 139
1995 167
1996 151
1997 131
1998 133
1999 93
2000 85
2001 69
2002 70
2003 67
2004 34
2005 44
2006 34
2007 27
2008 35
2009 30
2010 15
2011 22
2012 23
2013 21
2014 19
2015 17
2016 20
2017 10
2018 12
2019 2
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

4,493 results
Results by year
Filters applied: . Clear all
Page 1
Alternate-day therapy with omeprazole for duodenal ulcer.
Dhawan P, et al. Indian J Gastroenterol 1993 - Clinical Trial. PMID 8270292
RESULTS: MAO and PAO showed significant reduction in both duodenal ulcer patients and healthy controls 24 hours after 20 mg omeprazole. Reduction at 48 hours was significant in duodenal ulcer patients but not in controls. Endoscopic healing rates of duodenal ulcer at 2 and 4 weeks were 80% and 93.3% respectively in the daily treatment group and 71.4% and 85.7% respectively in the alternate-day treatment group. ...
RESULTS: MAO and PAO showed significant reduction in both duodenal ulcer patients and healthy controls 24 hours after 20 mg om …
[Drug therapy of ulcer disease].
Andrejević M. Srp Arh Celok Lek 1981. PMID 7323888 Serbian.
The H2-receptor antagonist era in duodenal ulcer disease.
Marks IN. Yale J Biol Med 1992 - Review. PMID 1364125 Free PMC article.
This paper reviews the remarkable impact of H2-receptor antagonists on duodenal ulcer management. The development and the scientific rationale of these agents are presented, and efficacy and safety aspects in the short- and long-term treatment of duodenal ulcer disease discussed. Attention is focused on the possible role of "acid rebound" in ulcer relapse following the withdrawal of therapy and on the clinical relevance of prolonged suppression of acid secretion in patients on long-term therapy....
This paper reviews the remarkable impact of H2-receptor antagonists on duodenal ulcer management. The development and the scie …
[Nizatidine]
Romero M and Franzosi MG. Medicina (Firenze) 1989 - Review. PMID 2567957 Italian.
Rate of healing for both duodenal and gastric ulcers and reduction in the rate of relapse are comparable to those of ranitidine....
Rate of healing for both duodenal and gastric ulcers and reduction in the rate of relapse are comparable to those of ranitidine....
Long term treatment of duodenal ulcer. A review of management options.
Bianchi Porro G and Parente F. Drugs 1991 - Review. PMID 1706986
Duodenal ulcer is a chronic disease characterised by remission and relapses. The duration of this relapsing tendency is unpredictable for the individual patient, but in most cases it lasts for many years and perhaps the entire lifetime. ...Continuous maintenance treatment with the currently available H2-blockers has proved to be superior to all the other strategies in terms of efficacy, and should therefore be regarded as the long term treatment of choice for duodenal ulcer patients. ...
Duodenal ulcer is a chronic disease characterised by remission and relapses. The duration of this relapsing tendency is unpred
Cigarette smoking and duodenal ulcer.
Hull DH and Beale PJ. Gut 1985. PMID 4085909 Free PMC article.
Tobacco smoking delays healing of gastric ulcer and may influence duodenal ulceration. Seventy men, all cigarette smokers, were found to have duodenal ulceration at endoscopy. ...We conclude that continued cigarette smoking does not prevent the powerful duodenal ulcer healing effect of cimetidine but does predispose to an increased expectation of duodenal ulceration soon after cimetidine has been stopped....
Tobacco smoking delays healing of gastric ulcer and may influence duodenal ulceration. Seventy men, all cigarette smokers, wer …
Safety profile of long-term H2-antagonist therapy.
Lewis JH. Aliment Pharmacol Ther 1991 - Review. PMID 1679672
The safety profile of low-dose maintenance therapy with H2-antagonists for duodenal ulcer disease suggests that these agents can be given safely for several years and probably much longer. ...Currently, H2-blockers and sucralfate are the only agents approved by the Food and Drug Administration for maintenance therapy of duodenal ulcer disease. ...
The safety profile of low-dose maintenance therapy with H2-antagonists for duodenal ulcer disease suggests that these a …
Sucralfate
Richardson CT. Ann Intern Med 1982. PMID 6896615
4,493 results
Jump to page
Feedback